ZONGERTINIB - Generic Drug Details

What are the generic drug sources for zongertinib and what is the scope of freedom to operate?

Zongertinib is the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Zongertinib has one hundred and three patent family members in forty-three countries.

One supplier is listed for this compound.

Summary for ZONGERTINIB

International Patents:	103
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	8
Patent Applications:	14
What excipients (inactive ingredients) are in ZONGERTINIB?	ZONGERTINIB excipients list
DailyMed Link:	ZONGERTINIB at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZONGERTINIB

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZONGERTINIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boehringer Ingelheim	PHASE3
Boehringer Ingelheim	PHASE2
Boehringer Ingelheim	PHASE1

See all ZONGERTINIB clinical trials

Pharmacology for ZONGERTINIB

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors HER2/Neu/cerbB2 Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for ZONGERTINIB

L01EH	Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for ZONGERTINIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	HERNEXEOS	zongertinib	TABLET;ORAL	219042-001	Aug 8, 2025		RX	Yes	Yes			Y	Y
Boehringer Ingelheim	HERNEXEOS	zongertinib	TABLET;ORAL	219042-001	Aug 8, 2025		RX	Yes	Yes			Y	Y
Boehringer Ingelheim	HERNEXEOS	zongertinib	TABLET;ORAL	219042-001	Aug 8, 2025		RX	Yes	Yes

International Patents for ZONGERTINIB

Country	Patent Number	Title	Estimated Expiration
South Korea	20250016507
Costa Rica	20220537
South Korea	20080070064
Austria	E446294
Japan	2010270154
Luxembourg	C00217
Mexico	2022013223

Supplementary Protection Certificates for ZONGERTINIB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1971601	SPC/GB21/042	United Kingdom		PRODUCT NAME: TUCATINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU/1/20/1526(FOR NI) 20210212; UK FURTHER MAS ON IPSUM 20210212
1971601	C20210018 00331	Estonia		PRODUCT NAME: TUKATINIIB;REG NO/DATE: EU/1/20/1526 12.02.2021
1971601	C01971601/01	Switzerland		PRODUCT NAME: TUCATINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67798 07.05.2020
1971601	21C1031	France		PRODUCT NAME: TUCATINIB, OPTIONNELLEMENT SOUS LA FORME D'UN SEL OU D'UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/20/1526 20210212
1971601	132021000000128	Italy		PRODUCT NAME: TUCATINIB OPZIONALMENTE NELLA FORMA DI UN SALE O SOLVATO FARMACEUTICAMENTE ACCETTABILE(TUKYSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1526, 20210212
1971601	CR 2021 00025	Denmark		PRODUCT NAME: TUCATINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/20/1526 20210212
1971601	LUC00217	Luxembourg		PRODUCT NAME: TUCATINIB EVENTUELLEMENT SOUS FORME D'UN SEL OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/20/1526 20210212

Zongertinib Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the current development stage of zongertinib?

Zongertinib, a next-generation epidermal growth factor receptor (EGFR) inhibitor, is primarily in early clinical development. As of 2023, it has entered Phase 1/2 trials targeting non-small cell lung cancer (NSCLC) with EGFR mutations. No approved indications or commercial sales exist at this time.

What are the competitive advantages of zongertinib?

Zongertinib's design aims at overcoming resistance mechanisms associated with first- and second-generation EGFR inhibitors, particularly T790M mutations. Early data suggests improved CNS penetration and activity in patients with brain metastases. Its selectivity profile may reduce off-target effects seen with existing drugs like osimertinib.

What is the potential market size for zongertinib?

The global NSCLC therapeutics market is valued at approximately $16 billion in 2023 and is projected to grow at a CAGR of 9% through 2030[1]. EGFR-mutant NSCLC accounts for 10-15% of all NSCLC cases, equating to roughly 1.6-2.4 million cases annually worldwide[2].

Within this segment, the first-line EGFR inhibitor market exceeds $5 billion, including osimertinib with approximately 50% market share[3]. A successful second-line or resistance-overcoming drug like zongertinib could capture a segment of this high-value market, particularly if it demonstrates efficacy in overcoming T790M mutations and CNS penetration.

What are the key factors influencing zongertinib's commercial outlook?

Clinical efficacy

• Demonstration of superior efficacy over existing EGFR inhibitors, especially in resistant settings and brain metastases.
• Favorable safety and tolerability profile to enable line extension.

Regulatory pathway

• Approval timelines depend on Phase 2/3 trial results.
• Accelerated approval possibilities could reduce time-to-market if early data is compelling.

Market penetration

• Existing competition from osimertinib, almonertinib, and other emerging agents.
• Ability to demonstrate clear clinical benefit over established therapies.

Manufacturing and pricing

• Cost of production will affect profitability.
• Pricing strategies will be influenced by competitive landscape and payer negotiations.

What are the projected financial trajectories?

Given no commercial launch yet, the financial forecast hinges on successful clinical development and regulatory approval. Factors include:

• Development costs: Estimated at $300 million to $500 million for Phase 1/3 trials, with costs rising as trials expand globally.
• Market entry valuation: Upon market access, sales could reach $1.5 billion annually within five years if zongertinib captures 10% of the EGFR-mutant NSCLC market. This estimate considers the drug's potential to address unmet needs, especially among patients with CNS metastases.
• Pricing assumptions: An annual price of $150,000 per patient aligns with current EGFR-TKI costs[4].

Financial modeling (simplified)

Assumption	Figures	Notes
Peak sales	$1.5 billion	Based on 10% market share of EGFR-mutant NSCLC segment
Development costs	$400 million	Typical for late-stage oncology drugs
Time to approval	5 years	From Phase 1 initiation
License fees	20% of sales	To licensing partners or co-marketers

This scenario presumes successful trial results and favorable regulatory outcomes, with break-even within 7-10 years post-launch.

What are the risks impacting market and financial access?

• Clinical failure: Negative trial outcomes could delay or prevent approval.
• Market competition: First-to-market advantage is critical; late entrants may struggle to gain share.
• Pricing pressures: Payers may limit reimbursement in highly competitive segments.
• Manufacturing delays: Supply chain disruptions could hinder timely launch and scale-up.
• Regulatory hurdles: Unanticipated safety issues could prolong approval timelines or reduce labeling.

What are the strategic considerations for stakeholders?

• Accelerate clinical development to mitigate late-stage competition risks.
• Develop companion diagnostics to identify suitable patient populations.
• Form alliances with established oncology companies to enhance market access.
• Invest in biomarker research for resistance mechanisms.

Key Takeaways

Zongertinib is at an early clinical phase with potential to address unmet needs in EGFR-mutant NSCLC. Its competitive position depends on demonstrating superiority in efficacy, especially in CNS metastases. Market opportunities are substantial but challenged by existing EGFR inhibitors. Financial success requires navigated regulatory pathways, efficient manufacturing, and strategic partnerships. The drug’s future hinges on clinical trial outcomes and market acceptance.

FAQs

1. When is zongertinib expected to reach the market?
A typical development timeline suggests regulatory approval could occur approximately 7-8 years from initiation, assuming positive trial results.

2. What competitive therapies could limit zongertinib’s market uptake?
Osimertinib remains the dominant EGFR inhibitor, with additional competitors like almonertinib and furmonertinib gaining traction.

3. Can zongertinib treat other cancers?
Potential exists if EGFR mutations or resistance pathways are relevant. Currently, its development targets NSCLC; broader indications remain exploratory.

4. What clinical data is needed for further advancement?
Proof of improved progression-free survival, CNS activity, and safety profile compared to existing therapies.

5. How could pricing influence market adoption?
High prices may limit access unless justified by superior efficacy or reduced toxicity, especially amidst competitive pressures.

---

References

[1] Grand View Research. (2023). Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis.
[2] American Cancer Society. (2021). Key statistics for lung cancer.
[3] Evaluate Pharma. (2023). Oncology Market Data.
[4] Express Scripts. (2022). Oncology drug pricing report.

Note: All data are estimates or projections based on publicly available sources and market analyses as of 2023.